You are here

  • Home
  • Archive
  • Volume 21, Issue 6
  • In individuals at intermediate risk for cardiovascular disease, treatment with rosuvastatin but not candesartan plus hydrochlorothiazide lowers cardiovascular disease event rates

Article metrics

Article menu
Download PDFPDF
Therapeutics/Prevention
Randomised controlled trial
In individuals at intermediate risk for cardiovascular disease, treatment with rosuvastatin but not candesartan plus hydrochlorothiazide lowers cardiovascular disease event rates

 

Online download statistics by month:

Online download statistics by month: October 2016 to March 2024

AbstractFullPdf
Oct 20162671325
Nov 2016199915
Dec 20161641036
Jan 201787911
Feb 20172213
Mar 20172751
Apr 20175810
May 20174300
Jun 20172153
Jul 20174010
Aug 20176232
Sep 20173910
Oct 20175731
Nov 20177442
Dec 20173910
Jan 20187654
Feb 20186741
Mar 20185620
Apr 20185732
May 20184943
Jun 20185751
Jul 20183810
Aug 20185420
Sep 20184223
Oct 20185423
Nov 20185421
Dec 20186621
Jan 20196332
Feb 20196532
Mar 20196320
Apr 20195100
May 20194410
Jun 20195200
Jul 20195410
Aug 20194201
Sep 20194800
Oct 20194210
Nov 20192800
Dec 20194931
Jan 20203800
Feb 20205700
Mar 20201700
Apr 20202010
May 20202010
Jun 20201900
Jul 20201911
Aug 20201100
Sep 20205101
Oct 20203611
Nov 20203710
Dec 20203200
Jan 20212600
Feb 20213000
Mar 20212800
Apr 20212500
May 20212800
Sep 2021300
Oct 20211000
Nov 20212100
Dec 20214310
Jan 20221310
Feb 20225200
Mar 20222910
Apr 20222132
May 20224700
Jun 20224200
Jul 20221910
Aug 20224730
Sep 20223000
Oct 20224600
Nov 20222300
Dec 20222400
Jan 20232511
Feb 20237310
Mar 2023800
Apr 20231600
May 20232111
Jul 20231400
Aug 20231000
Sep 2023600
Oct 20231200
Nov 20233400
Dec 20234821
Jan 20243311
Feb 20241510
Mar 20244321
Total3792138134